My Personalized Breast Screening

MyPeBS is an international randomized, open‐label, multicentric, study assessing the effectiveness of a risk‐based breast cancer screening strategy (using clinical risk scores and polymorphisms) compared to standard screening (according to the current national guidelines in each participating country) in detecting stage 2 or higher breast cancers. Women will be differentially screened for 4 years and then, after an end‐of‐study mammogram, they will return to the routine screening practice. The main study endpoint will be measured at the end of the four years of intervention. Furthermore, follow up data will be collected for 15 years from study entry for evaluation of long‐term cumulative breast cancer incidence and breast cancer‐specific survival